Radiation Injuries Clinical Trial
Official title:
The Effect of Thalidomide in Radiation-induced Brain Injury（RI）: a Phase II Clinical Trial
Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects
and side effects of thalidomide in radiation-induced brain injury.
Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University /
Yameitang.
Primary outcome measure: The primary endpoint is the brain injury remission at week 15. In
brief, the brain lesion will be evaluated by using brain MRI scan before and after
thalidomide regimen. The clinical efficacy is defined as ≥ 25% reduction in brain edema
volume on FLAIR images at week 15, as compared with that before thalidomide usage.
There is no acknowledged and effective standard treatment for radiation-induced brain injury
(RI). Glucocorticoids and bevacizumab during acute period are optional ways to reduce the
brain edema. However, glucocorticoids and bevacizumab are unsuitable or ineffective for some
patients, especially in the early stage of RI. The investigators supposed that angiogenesis
might play a key role in the pathogenesis of RI, and that thalidomide, as an antiangiogenic
drug, would reduce immature angiogenesis and improve vessel maturation in RI.
Primary objectives: This phase II clinical trial aims to evaluate the indications,
therapeutic effects and safety of thalidomide in radiation-induced brain injury.
OUTLINE: This is a phase II, open-label, single arm clinical trial. Patients are enrolled and
administrated with thalidomide. Thalidomide is supplied as 25 mg per pill to be taken by
mouth.
Arm І: Patients receive thalidomide with a dosage of 25 mg at bedtime daily one week (days
1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for
one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the
absence of unacceptable toxicity or severe deterioration.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
| Completed |
NCT02985164 -
Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography
|
Phase 3 | |
| Recruiting |
NCT04152681 -
Effect and Safety of Apatinib on Radiation-Induced Brain Injury
|
Phase 2 | |
| Recruiting |
NCT04818099 -
Vortioxetine in the Treatment of Depression Associated With Head and Neck Cancers Undergoing Radiotherapy
|
Phase 3 | |
| Completed |
NCT03667859 -
Vaginal Elasticity Assessment Before and After Brachytherapy/Pelvic Radiation
|
||
| Terminated |
NCT03660618 -
LSFG-SKIN, Laser Speckle Flowgraphy
|
N/A | |
| Completed |
NCT00725244 -
Trial of Endoscopy Bipolar and Argon of Chronic Rectal Bleeding From Radiation Telangiectasias
|
Phase 4 | |
| Completed |
NCT00001523 -
Structure and Functional Status of Parotid Glands Exposed to Therapeutic Irradiation
|
N/A | |
| Not yet recruiting |
NCT06325982 -
Clinical Observation of Drug Retention Enema in Preventing Acute Radiation-induced Rectal Injury
|
N/A | |
| Recruiting |
NCT03907371 -
The Effect of Donepezil in Radiotherapy-related Cognitive Impairment.
|
Phase 2 | |
| Not yet recruiting |
NCT05063773 -
Novel Wireless Mixed Reality Headset for Image Guidance in Cardiac Catheterization Laboratory
|
N/A | |
| Completed |
NCT00001437 -
Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis
|
Phase 2 | |
| Completed |
NCT02972736 -
RadiatiOn Dose Among Different EndOvascular Procedures: the RODEO Study
|
N/A | |
| Completed |
NCT02104271 -
Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.
|
Phase 2 | |
| Terminated |
NCT00134628 -
Study to Determine if Hyperbaric Oxygen Therapy is Helpful for Treating Radiation Tissue Injuries
|
Phase 3 | |
| Completed |
NCT03961217 -
Return to Work Among Cancer Survivors With Treatment-induced Survivorship Syndromes
|